Axcan Intermediate Holdings Inc., Axcan Pharma Inc.'s parent company (together "Axcan" or the "Company") today announc...
ABSTRACT The effects of neuroactive compounds on larval metamorphosis of the Japanese short neck clam Ruditapes phi...
You routinely administer combination drugs...but do you know what's in them? To find out, match each combination of ingr...
After a 20-month investigation, Federal criminal bribery and fraud charges have been filed against 29 people for parti...
Chancroid is a common sexually transmitted disease (STD) caused by infection with the Gram negative bacterium Haemoph...
DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications.